Dana Farber Cancer Institute

Site:	Dana Farber Cancer Institute	Go to their website
Address:	450 Brookline Ave
City:	Boston
State:	MA
Zip:	02215-5450
Country:	USA

70 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [desc]	NCT#
1	Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)	Completed	Closed	IPI-504	NCT00276302
1	BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)	Completed	Closed	Infigratinib + Imatinib	NCT02257541.
1	Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)	Completed	Closed	Imatinib and Nilotinib	NCT00135005
2	Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors	Completed	Closed	Imatinib + RAD001	NCT01275222
1	A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients	Completed	Closed	Imatinib + BKM120	NCT01468688
2	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST	Completed	Closed	Imatinib + AT13387	NCT01294202
3	Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients	Terminated	Closed	Imatinib	NCT01031628
2	A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing c-Kit Gene (Extension of US Phase II study, B2222)	Completed	Closed	Imatinib	NCT00237185
2	Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)	Completed	Closed	Imatinib	NCT00867113
1	A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST1]	Recruiting	Active	IDRX-42	NCT05489237
1	A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma	Ongoing, but not recruiting	Closed	GDC-0980	NCT00854126
1	A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma	Completed	Closed	GDC-0980	NCT00854152
1	A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered Daily in Patients With Locally Advanced or Metastatic Solid Tumors	Completed	Closed	GDC-0941 + GDC-0973	NCT00996892
1	A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable	Ongoing, but not recruiting	Closed	GDC-0941	NCT00876109
1	DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	DS-6157a	NCT04276415
1/2	A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)	Recruiting	Active	DCC-3009	NCT06630234
2	Trial of Dasatinib in Advanced Sarcomas	Ongoing, but not recruiting	Closed	Dasatinib (BMS-354825)	NCT00464620
1	Phase I (PH I) Mad Refractory Solid Tumor Study	Completed	Closed	Dasatinib (BMS-354825)	NCT00099606
1	RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms	Ongoing, but not recruiting	Closed	CP-751,871 + RAD001	NCT00927966
1	A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors	Ongoing, but not recruiting	Closed	Cobimetinib + MPDL3280A	NCT01988896

Dana Farber Cancer Institute

70 trials at this site

First | Previous | Page 3 of 4 | Next | Last